Study on the Utilization of Cabozantinib in Adult Patients With Advanced or Metastatic Renal Cell Carcinoma (RCC) in 2nd Line Treatment Following Prior Vascular Endothelial Growth Factor (VEGF)-Targeted Therapy Under Real-real Life Clinical Setting in France.
NCT04609800 · Status: WITHDRAWN · Type: OBSERVATIONAL
Last updated 2020-12-21
Summary
The purpose of the protocol is to assess the Overall Survival (OS) at 1 year in patients after cabozantinib initiation.
Conditions
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ipsen Medical Director · Ipsen
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2020-11-06
- Primary Completion
- 2023-05-10
- Completion
- 2023-05-10
More Related Trials
-
Cabozantinib (XL-184) Monotherapy for Advanced Cholangiocarcinoma
NCT01954745 ·Status: COMPLETED ·Phase: PHASE2
-
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541 ·Status: RECRUITING ·Phase: PHASE1
-
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
NCT00048126 ·Status: COMPLETED ·Phase: PHASE2
-
Phase II-b Randomized Clinical Trial of Cabazitaxel in Metastatic Colorectal Cancer Resistant to Standard Treatment
NCT02204332 ·Status: TERMINATED ·Phase: PHASE2
-
Capecitabine and Irinotecan in Treating Patients With Locally Advanced, Recurrent, or Metastatic Colorectal Cancer
NCT00022698 ·Status: COMPLETED ·Phase: PHASE2
-
Capecitabine and Temozolomide for Neuroendocrine Cancers
NCT00869050 ·Status: COMPLETED ·Phase: PHASE2
-
Study Evaluating the Safety, Pharmacokinetics (PK), Pharmacodynamics (PD), and Therapeutic Activity of Selicrelumab (RO7009789) With Vanucizumab or Bevacizumab in Participants With Metastatic Solid Tumors
NCT02665416 ·Status: COMPLETED ·Phase: PHASE1
-
2nd-line Treatment of Metastatic Colorectal Cancer
NCT01532804 ·Status: TERMINATED ·Phase: PHASE2
-
Irinotecan, Capecitabine and Bevacizumab in Metastatic Colorectal Cancer Patients
NCT00875771 ·Status: COMPLETED ·Phase: PHASE2
-
A Study of Xeloda (Capecitabine) in Patients With Advanced and/or Metastatic Colorectal Cancer
NCT00048139 ·Status: COMPLETED ·Phase: PHASE2
-
Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
NCT00107315 ·Status: TERMINATED ·Phase: PHASE2
-
Study of Capecitabine and Cetuximab as First-Line Therapy in Patients With Metastatic Wild Type Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Colorectal Cancer
NCT00954876 ·Status: WITHDRAWN ·Phase: PHASE2
-
Phase 2 Study of CA102N Combined With TAS-102 Compared to Bevacizumab Combined With TAS-102 in Subjects With Relapsed and/or Refractory Metastatic Colorectal Cancer
NCT06039202 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer
NCT00069095 ·Status: COMPLETED ·Phase: PHASE3
-
Bevacizumab and Combination Chemotherapy as First-Line Therapy in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
NCT00467142 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of the Combination of Rogaratinib With Copanlisib in Patients With Fibroblast Growth Factor Receptor (FGFR)-Positive, Locally Advanced or Metastatic Solid Tumors
NCT03517956 ·Status: COMPLETED ·Phase: PHASE1
-
Intra-arterial Hepatic Bevacizumab and Systemic Chemotherapy
NCT01677884 ·Status: COMPLETED ·Phase: PHASE2
-
Cap+Bev vs Cap+Iri+Bev 1st-line Therapy in mCRC
NCT01249638 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
NCT00443573 ·Status: SUSPENDED ·Phase: PHASE1/PHASE2
-
An Observational Study of Bevacizumab in Combination With 5-FU-Based Chemotherapy in Chinese Participants With Metastatic Colorectal Cancer
NCT01319877 ·Status: COMPLETED
-
Bevacizumab and Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer
NCT00544011 ·Status: UNKNOWN ·Phase: PHASE2
-
Study To Evaluate Safety, Pharmacokinetics, Pharmacodynamics, And Preliminary Anti-Tumor Activity Of RO7122290 In Combination With Cibisatamab With Obinutuzumab Pre-Treatment
NCT04826003 ·Status: COMPLETED ·Phase: PHASE1
-
A Study Evaluating S 95005 Plus Bevacizumab and Capecitabine Plus Bevacizumab in Patients With Previously Untreated Colorectal Cancer Who Are Non-eligible for Intensive Therapy
NCT02743221 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Neoadjuvant CT With Selective Radiotherapy in Patients With Intermediate-Risk Cancer Rectum
NCT00909987 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
NCT06128551 ·Status: RECRUITING ·Phase: PHASE1/PHASE2